ElevateBio

Executive Summary

ElevateBio is a private biotechnology company uniquely positioned to accelerate the development of cell and gene therapies through an integrated model that combines proprietary gene editing (Life Edit) with end-to-end cGMP manufacturing and process development (BaseCamp). Founded in 2017 and headquartered in Waltham, Massachusetts, the company serves as a platform enabler for genetic medicine developers, reducing time and cost from research to clinic. ElevateBio's dual capabilities address critical bottlenecks in the space: scalable manufacturing and cutting-edge editing tools. Despite being in the pre-clinical stage, its business model generates revenue through partnerships and services, providing a diversified risk profile. As demand for genetic medicines grows, ElevateBio is poised to capture value as both a service provider and technology innovator. The company's ability to attract top-tier collaborators and maintain operational excellence will be key to its long-term success.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major pharmaceutical partnership for BaseCamp manufacturing services70% success
• Q1 2027Advancement of a Life Edit gene-editing program into IND-enabling studies40% success
• Q4 2026Completion of a new GMP manufacturing facility to expand capacity80% success